ATP-dependent transport of statins by human and rat MRP2/Mrp2

Toxicology and Applied Pharmacology

Volumn 269, Issue 2, 2013, Pages 187-194

  Ellis, Lucy C J ^a   Hawksworth, Gabrielle M ^a   Weaver, Richard J ^b  

^a Section of Translational Medicine   (United Kingdom)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

ATPase assay; Drug interactions; MRP2; Pharmacokinetics; Statins; Vesicle assay

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 2; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BINDING SITE; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; IC 50; LIPOPHILICITY; NONHUMAN; PROTEIN EXPRESSION; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSECTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RATS;

RATTUS;

EID: 84876703460     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.03.019     Document Type: Article

References (49)

1. Backman J.T., Kyrklund C., Neuvonen M., Neuvonen P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 2002, 72:685-691.
2. Bodó A., Bakos É., Szeri F., Váradi A., Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol. Lett. 2003, 140:133-143.
3. Bogman K., Peyer A.K., Török M., Küsters E., Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 2001, 132:1183-1192.
4. Chang J.T., Staffa J.A., Parks M., Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004, 13:417-426.
5. Chapman M.J., McTaggart F. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler. Suppl. 2002, 2:33-37.
6. Chen C., Mireles R.J., Campbell S.D., Lin J., Mills J.B., Xu J.J., Smolarek T.A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005, 33:537-546.
7. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999, 84:413-428.
8. Fernandez-Checa J.C., Takikawa H., Horie T., Ookhtens M., Kaplowitz N. Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. J. Biol. Chem. 1992, 267:1667-1673.
9. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 1998, 19:26-37.
10. Hinton L.K., Galetin A., Houston J.B. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm. Res. 2008, 25:1063-1074.
11. Hirano M., Maeda K., Hayashi H., Kusuhara H., Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 2005, 314:876-882.
12. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 2005, 68:800-807.
13. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006, 34:1229-1236.
14. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., Kirchgessner T.G. A novel human hepatic organic anion transporting polypeptide (OATP2). J. Biol. Chem. 1999, 274:37161-37168.
15. Huang L., Wang Y., Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 2006, 34:738-742.
16. Ishigami M., Honda T., Takasaki W., Ikeda T., Komai T., Ito K., Sugiyama Y. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 2001, 29:282-288.
17. Kajinami K., Takekoshi N., Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drugs Rev 2003, 21:199-215.
18. Kantola T., Kivistö K.T., Neuvonen P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 1998, 64:58-65.
19. Kantola T., Kivistö K.T., Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 1998, 64:177-182.
20. Kitamura S., Maeda K., Wang Y., Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008, 36:2014-2023.
21. Kitamura T., Jansen P., Hardenbrook C., Kamimoto Y., Gatmaitan Z., Arias I.M. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc. Natl. Acad. Sci. 1990, 87:3557.
22. Kivistö K.T., Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 2007, 24:239-247.
23. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005, 352:1425-1435.
24. Lau Y.Y., Okochi H., Huang Y., Benet L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006, 34:1175-1181.
25. Lewis S.J., Sacks F.M., Mitchell J.S., East C., Glasser S., Kell S., Letterer R., Limacher M., Moye L.A., Rouleau J.L. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J. Am. Coll. Cardiol. 1998, 32:140-146.
26. Link J.T., Sorensen B.K., Lai C., Wang J., Fung S., Deng D., Emery M., Carroll S., Grynfarb M., Goos-Nilsson A. Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids. Bioorg Med Chem Lett 2004, 14:4173-4178.
27. Lowe P.J., Hijazi Y., Luttringer O., Yin H., Sarangapani R., Howard D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 2007, 37:1331-1354.
28. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler. Suppl. 2003, 4:9-14.
29. Neuvonen P.J., Jalava K.-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 1996, 60:54-61.
30. Niemi M., Arnold K.A., Backman J.T., Pasanen M.K., Gödtel-Armbrust U., Wojnowski L., Zanger U.M., Neuvonen P.J., Eichelbaum M., Kivistö K.T. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006, 16:801.
31. Niemi M., Schaeffeler E., Lang T., Fromm M.F., Neuvonen M., Kyrklund C., Backman J.T., Kerb R., Schwab M., Neuvonen P.J. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenet Genomics 2004, 14:429.
32. Ninomiya M., Ito K., Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab Dispos 2005, 33:225-232.
33. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003, 73:554-565.
34. Pedersen T.R., Kjekshus J., Berg K., Olsson A.G., Wilhelmsen L., Wedel H., Pyörälä K., Miettinen T., Haghfelt T., Færgeman O. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996, 93:1796-1802.
35. Plehn J.F., Davis B.R., Sacks F.M., Rouleau J.L., Pfeffer M.A., Bernstein V., Cuddy T.E., Moyé L.A., Piller L.B., Rutherford J. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999, 99:216-223.
36. Poirier A., Funk C., Lavé T., Noé J. New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Disc Dev 2007, 10:74.
37. Reinoso R.F., Sanchez N.A., Garcia M.J., Prous J.R. Pharmacokinetic interactions of statins. Methods Find Exp Clin Pharmacol 2001, 23:541-566.
38. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 2012, 92:50-61.
39. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., Lasseter K.C., Brown C.D.A., Windass A.S., Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 2004, 75:455-463.
40. Shitara Y., Hirano M., Sato H., Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 2004, 311:228-236.
41. Shitara Y., Horie T., Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 2006, 27:425-446.
42. Shitara Y., Itoh T., Sato H., Li A.P., Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003, 304:610-616.
43. Tokui T., Nakai D., Nakagomi R., Yawo H., Abe T., Sugiyama Y. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, OATP2. Pharm Res 1999, 16:904-908.
44. Van Aubel R.A.M.H., Smeets P.H.E., van den Heuvel J.J.M.W., Russel F.G.M. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 2005, 288:F327-F333.
45. Weaver R.J., Jochemsen R. Nonclinical pharmacokinetics and toxicokinetics. International Pharmaceutical Product Registration 2009, 220:336-376. Informa Press. C. Antony, Cartwright, B.R. Mathews (Eds.).
46. Yamazaki M., Akiyama S., Ni'inuma K., Nishigaki R., Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 1997, 25:1123-1129.
47. Yamazaki M., Akiyama S., Nishigaki R., Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 1996, 13:1559-1564.
48. Yamazaki M., Tokui T., Ishigami M., Sugiyama Y. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos 1996, 17:775-789.
49. Zelcer N., Huisman M.T., Reid G., Wielinga P., Breedveld P., Kuil A., Knipscheer P., Schellens J.H.M., Schinkel A.H., Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 2003, 278:23538-23544.